Fintel reports that Fmr
has filed a 13G/A form
with the SEC disclosing ownership of
9.17MM
shares of Sana Biotechnology, Inc. (SANA).
This represents 4.807% of the company.
In their previous filing dated May 19, 2022
they reported 9.49MM shares and 5.00% of the company,
a decrease in shares of 3.41%
and
a decrease in total ownership of
0.20% (calculated as current – previous percent ownership).
Analyst Price Forecast Suggests 110.60% Upside
As of February 9, 2023,
the average one-year price target for Sana Biotechnology is $9.44.
The forecasts range from a low of $5.05 to a high of $13.65.
The average price target represents an increase of 110.60% from its latest reported closing price of $4.48.
The projected annual revenue for Sana Biotechnology
is $0MM.
The projected annual EPS
is -$2.49.
What is the Fund Sentiment?
There are 295 funds or institutions reporting positions in Sana Biotechnology.
This is a decrease
of
2
owner(s) or 0.67% in the last quarter.
Average portfolio weight of all funds dedicated to SANA is 0.09%,
an increase
of 30.19%.
Total shares owned by institutions increased
in the last three months by 3.78% to 133,534K shares.
The put/call ratio of SANA is 0.32, indicating a
bullish
outlook.
What are large shareholders doing?
Flagship Pioneering
holds 34,239K shares
representing 18.03% ownership of the company.
No change in the last quarter.
Baillie Gifford &
holds 10,765K shares
representing 5.67% ownership of the company.
In it’s prior filing, the firm reported owning 10,967K shares, representing
a decrease
of 1.88%.
The firm
decreased
its portfolio allocation in SANA by 75.72% over the last quarter.
Canada Pension Plan Investment Board
holds 10,175K shares
representing 5.36% ownership of the company.
No change in the last quarter.
Public Sector Pension Investment Board
holds 6,400K shares
representing 3.37% ownership of the company.
No change in the last quarter.
XBI – SPDR Biotech ETF
holds 4,686K shares
representing 2.47% ownership of the company.
In it’s prior filing, the firm reported owning 6,973K shares, representing
a decrease
of 48.81%.
The firm
decreased
its portfolio allocation in SANA by 37.22% over the last quarter.
Sana Biotechnology Background Information
(This description is provided by the company.)
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. Sana shares a vision of repairing and controlling genes, replacing missing or damaged cells, and making its therapies broadly available to patients. Sana is more than 250 people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, and South San Francisco.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
